Capmatinib (INC280), an oral ATP-competitive and highly potent MET inhibitor, was tested in a phase I clinical trial (NCT01324479, https://clinicaltrials.gov/study/NCT01324479, accessed on 27 October 2024), and the results showed an acceptable safety profile and antitumor activity in certain MET-positive solid tumors, including glioblastoma [157]. Here, MET is linked to glioblastoma.